Stock Events

Stock Events

Hard to Treat Diseases 

$0.000020
1
+$0.00+0%Wednesday 20:00

Statistics

Day High
0.000001
Day Low
0.000001
52W High
0.00002
52W Low
0.000001
Volume
1
Avg. Volume
0
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences focuses on antiviral drugs to treat diseases like HIV, hepatitis B, hepatitis C, and influenza, directly competing in the treatment of hard-to-treat diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals is known for its treatments for cystic fibrosis, a hard-to-treat genetic disorder, making it a direct competitor in the field of complex diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, including a range of hard-to-treat diseases, through its innovative biotechnology.
AMGEN
AMGN
Mkt Cap217.9B
Amgen focuses on human therapeutics, including treatments for illnesses considered hard to treat, such as cancer and cardiovascular disease.
Biogen
BIIB
Mkt Cap32.49B
Biogen targets neurological and neurodegenerative diseases, competing in the space of hard-to-treat conditions with its advanced therapies.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie works on significant chronic diseases like rheumatoid arthritis, psoriasis, Crohn's disease, and other hard-to-treat conditions, making it a competitor.
Novartis
NVS
Mkt Cap268B
Novartis offers diversified medications, including treatments for hard-to-treat diseases across several therapeutic areas, competing on a broad scale.
Pfizer
PFE
Mkt Cap158.45B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including hard-to-treat diseases, making it a key competitor.
Merck
MRK
Mkt Cap356.01B
Merck is known for its contributions to healthcare, including vaccines and treatments for hard-to-treat diseases, positioning it as a competitor.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its pharmaceutical division, addresses a wide array of health conditions, including hard-to-treat diseases, making it a competitor in the healthcare sector.

About

Hard to Treat Diseases Inc. (HTDS), founded in 2009 and headquartered in Shenzhen, China, is a pharmaceutical firm engaged in the development, manufacturing, and global export of biopharmaceutical products and vaccines. The company's extensive portfolio includes a range of biological agents such as reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection. HTDS also provides various chemical pharmaceuticals, including cobratide injection, entecavir capsules, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection. Additionally, it supplies critical vaccines for rabies, ACYW135 meningococcal disease, influenza, Hepatitis A, and varicella. HTDS distributes its offerings through a sales network primarily focused on markets in South Asia, Southeast Asia, Central and South America, and the Middle East.
Show More
CEO
Terry Yuan
Country
United States
ISIN
US41164A1034

Listings

OTC Link
US
HTDS

0 Comments

Share your thoughts

FAQs

What is Hard to Treat Diseases stock price today?▼
The current price of HTDS is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Hard to Treat Diseases stock price performance more closely on the chart.
What is Hard to Treat Diseases stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Hard to Treat Diseases stocks are traded under the ticker HTDS.
Is Hard to Treat Diseases stock price growing?▼
HTDS stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Hard to Treat Diseases has showed a +0% increase.
In which sector is Hard to Treat Diseases located?▼
Hard to Treat Diseases operates in the Health & Wellness sector.
When did Hard to Treat Diseases complete a stock split?▼
Hard to Treat Diseases has not had any recent stock splits.
Where is Hard to Treat Diseases headquartered?▼
Hard to Treat Diseases is headquartered in Clearwater, United States.